Description Benitec Biopharma Ltd. ADR

Benitec Biopharma Ltd. engages in the development of therapeutics based on patented gene silencing technology called ddRNAi. It develops treatments for chronic and life threatening human conditions, such as oculopharyngeal muscular dystrophy, oncology, wet age-related macular degeneration, and hepatitis B. It operates through the Australia and USA geographical segments. The company was founded by Kenneth C. Reed in 1997 and is headquartered in North Sydney, Australia.

Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.